Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Common Stock: ¥435 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603676 Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
78 GF Score
Price ¥9.35
GF Value ¥8.91
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Xizang Weixinkang Pharmaceutical Co Common Stock?

Xizang Weixinkang Pharmaceutical Co SHSE:603676 +0.75% 78 Common Stock is ¥435 Mil as of Mar. 2026. GuruFocus rates SHSE:603676 with a GF Score™ of 78/100 and a GF Value™ of ¥8.91 (Fairly Valued). The stock has 2 warning signs investors should review.

Xizang Weixinkang Pharmaceutical Co's quarterly common stock stayed the same from Sep. 2025 (¥435 Mil) to Dec. 2025 (¥435 Mil) and stayed the same from Dec. 2025 (¥435 Mil) to Mar. 2026 (¥435 Mil).

Xizang Weixinkang Pharmaceutical Co's annual common stock stayed the same from Dec. 2023 (¥435 Mil) to Dec. 2024 (¥435 Mil) and stayed the same from Dec. 2024 (¥435 Mil) to Dec. 2025 (¥435 Mil).

Xizang Weixinkang Pharmaceutical Co Common Stock Historical Data

* Premium members only.

The historical data trend for Xizang Weixinkang Pharmaceutical Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xizang Weixinkang Pharmaceutical Co Common Stock Chart

Xizang Weixinkang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 435.92 435.16 435.16 435.16 435.16

Xizang Weixinkang Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 435.16 435.16 435.16 435.16 435.16
SHSE:603676
78GF Score
Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xizang Weixinkang Pharmaceutical Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of ¥435 Mil mean?
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a Common Stock of ¥435 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors.
Is Xizang Weixinkang Pharmaceutical Co's Common Stock too high?
Xizang Weixinkang Pharmaceutical Co's current Common Stock is ¥435 Mil. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's Common Stock compare to ZTS?
Xizang Weixinkang Pharmaceutical Co's Common Stock of ¥435 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. Xizang Weixinkang Pharmaceutical Co's current Common Stock is ¥435 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.91, compared to a current price of ¥9.35 — trading 4.9% above its estimated fair value. The current Common Stock is ¥435 Mil. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current Common Stock is ¥435 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?

Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥9.35 is trading 4.9% above its estimated GF Value™ of ¥8.91. GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603676:

  • Common Stock: ¥435 Mil
  • GF Value™: ¥8.91 vs. price of ¥9.35 (4.9% above fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xizang Weixinkang Pharmaceutical Co Business Description

Address Yuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
78GF Score

Get the complete analysis for SHSE:603676

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.35
Price
¥8.91
GF Value